Evermay Wealth Management LLC lowered its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Rating) by 25.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 463 shares of the exchange traded fund’s stock after selling 155 shares during the quarter. Evermay Wealth Management LLC’s holdings in SPDR S&P Biotech ETF were worth $38,000 at the end of the most recent quarter.
A number of other institutional investors have also added to or reduced their stakes in the company. Barclays PLC increased its stake in SPDR S&P Biotech ETF by 26.1% in the third quarter. Barclays PLC now owns 1,383,583 shares of the exchange traded fund’s stock valued at $109,745,000 after acquiring an additional 286,345 shares during the last quarter. Two Sigma Advisers LP bought a new position in SPDR S&P Biotech ETF in the third quarter valued at $105,480,000. Hsbc Holdings PLC increased its stake in SPDR S&P Biotech ETF by 23.0% in the third quarter. Hsbc Holdings PLC now owns 974,615 shares of the exchange traded fund’s stock valued at $78,771,000 after acquiring an additional 182,486 shares during the last quarter. Brown Advisory Inc. increased its stake in SPDR S&P Biotech ETF by 1,107.6% in the third quarter. Brown Advisory Inc. now owns 970,255 shares of the exchange traded fund’s stock valued at $76,960,000 after acquiring an additional 889,912 shares during the last quarter. Finally, LPL Financial LLC increased its stake in SPDR S&P Biotech ETF by 23.0% in the second quarter. LPL Financial LLC now owns 704,040 shares of the exchange traded fund’s stock valued at $52,289,000 after acquiring an additional 131,691 shares during the last quarter.
SPDR S&P Biotech ETF Stock Up 0.6 %
XBI opened at $74.19 on Monday. The stock has a market cap of $6.97 billion, a PE ratio of 11.47 and a beta of 1.00. SPDR S&P Biotech ETF has a 52 week low of $61.78 and a 52 week high of $97.19. The business’s fifty day simple moving average is $83.74 and its 200 day simple moving average is $82.27.
SPDR S&P Biotech ETF Company Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
See Also
- Get a free copy of the StockNews.com research report on SPDR S&P Biotech ETF (XBI)
- These Indicators Are Pointing To a Rally In Bank Of America, Soon
- Is Block a Ticking Time Bomb or a Bargain Bestowed by Hindenburg?
- These Bitcoin Stocks Have the Most Upside
- MarketBeat Week in Review – 3/20 – 3/24
- Dividend King Genuine Parts Company Upgraded On Profit Guidance
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Get Rating).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
